Q1 2012 Earnings Call
May 09, 2012 8:30 am ET
Lisa Wilson -
Richard M. Smith - Chief Executive Officer, President, Chief Operating Officer and Director
Hai V. Tran -
Mary Jane Graves - Chief Financial Officer and Treasurer
Brooks G. O'Neil - Dougherty & Company LLC, Research Division
Michael John Petusky - Noble Financial Group, Inc., Research Division
Kyle D. Smith - Jefferies & Company, Inc., Research Division
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the BioScrip First Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded on Wednesday, May 9, 2012.
I would now like to turn the conference over to Lisa Wilson, Investor Relations for BioScrip.
Good morning, and thank you for joining us today. By now you should have received a copy of our press release issued this morning. If you have not received it, you may access it through the Investor Relations section at our website.
Rick Smith, President and Chief Executive Officer and MJ Graves, Interim Chief Financial Officer and Treasurer, will host this morning's call. The call may be accessed through our website at bioscrip.com. A replay will be available shortly after the call. Interested parties can access the replay by dialing (800) 633-8284 in the U.S. and (402) 977-9140 internationally and entering access code 21590255. An audio webcast will also be available under the Investor Relations section of the BioScrip website at bioscrip.com.
Before we get started, I would like to remind everyone that any statements made on the call today or in our press release that express a belief, expectation or intent, as well as those that are historical facts are considered forward-looking statements and are protected under the Safe Harbor of the Private Securities Litigation and Reform Act. These forward-looking statements are based on information available to BioScrip today, and the company assumes no obligation to update statements as circumstances change. These forward-looking statements may involve a number of risks and uncertainties, which may cause the company's results to differ materially from such statements. Important factors that could cause such differences include the failure to realize annualized cost savings associated with any restructuring or cost reduction efforts, the ability of members of management to execute these efforts, the company's ability to leverage core competencies or maximize margin and operating cash flow and the company's ability to grow its Infusion segment organically or through acquisitions, as well as the risks described in the company's periodic filings with the Securities and Exchange Commission including BioScrip's annual report on Form 10-K for the year ended December 31, 2011.